Sofinnova Investments, Inc.: 13F holdings
CIK 16311342026Q2
| Positions | 56 |
|---|
| Reported value | $1.9bn |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 56 (-13 vs prior quarter) |
|---|
| Reported value | $1.9bn (-26.5%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| NTRA Natera Inc | 1,550,280 | $420.8m | 21.8% |
| VERA Vera Therapeutics Inc | 2,793,987 | $119.9m | 6.2% |
| GMAB Genmab A/S | 4,045,215 | $111.1m | 5.7% |
| Jazz Pharmaceuticals PLC | 365,341 | $88.0m | 4.6% |
| RAPP Rapport Therapeutics Inc | 1,904,408 | $79.4m | 4.1% |
| Seaport Therapeutics Inc | 3,564,871 | $77.4m | 4.0% |
| AVBP Arrivent BioPharma Inc | 1,696,752 | $58.9m | 3.0% |
| RARE Ultragenyx Pharmaceutical In | 1,717,505 | $57.3m | 3.0% |
| BIOA BioAge Labs Inc | 2,293,788 | $56.2m | 2.9% |
| BMY Bristol-Myers Squibb Co | 876,970 | $50.5m | 2.6% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1631134")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples